These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 14998588)
1. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Bos GW; Jacobs JJ; Koten JW; Van Tomme S; Veldhuis T; van Nostrum CF; Den Otter W; Hennink WE Eur J Pharm Sci; 2004 Mar; 21(4):561-7. PubMed ID: 14998588 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels. Hiemstra C; Zhong Z; Van Tomme SR; van Steenbergen MJ; Jacobs JJ; Otter WD; Hennink WE; Feijen J J Control Release; 2007 Jun; 119(3):320-7. PubMed ID: 17475360 [TBL] [Abstract][Full Text] [Related]
3. Biodegradable dextran hydrogels crosslinked by stereocomplex formation for the controlled release of pharmaceutical proteins. Hennink WE; De Jong SJ; Bos GW; Veldhuis TF; van Nostrum CF Int J Pharm; 2004 Jun; 277(1-2):99-104. PubMed ID: 15158973 [TBL] [Abstract][Full Text] [Related]
4. Crosslinked hyaluronan hydrogels containing mitomycin C reduce postoperative abdominal adhesions. Liu Y; Li H; Shu XZ; Gray SD; Prestwich GD Fertil Steril; 2005 Apr; 83 Suppl 1():1275-83. PubMed ID: 15831302 [TBL] [Abstract][Full Text] [Related]
5. Tissue reactions of in situ formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats. Bos GW; Hennink WE; Brouwer LA; den Otter W; Veldhuis TF; van Nostrum CF; van Luyn MJ Biomaterials; 2005 Jun; 26(18):3901-9. PubMed ID: 15626437 [TBL] [Abstract][Full Text] [Related]
6. Physically crosslinked dextran hydrogels by stereocomplex formation of lactic acid oligomers: degradation and protein release behavior. de Jong SJ; van Eerdenbrugh B; van Nostrum CF; Kettenes-van den Bosch JJ; Hennink WE J Control Release; 2001 Apr; 71(3):261-75. PubMed ID: 11295219 [TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro anti-cancer activity of thermo-sensitive and photo-crosslinkable doxorubicin hydrogels composed of chitosan-doxorubicin conjugates. Cho YI; Park S; Jeong SY; Yoo HS Eur J Pharm Biopharm; 2009 Sep; 73(1):59-65. PubMed ID: 19409990 [TBL] [Abstract][Full Text] [Related]
8. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. Lee F; Chung JE; Kurisawa M J Control Release; 2009 Mar; 134(3):186-93. PubMed ID: 19121348 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model. De Groot CJ; Cadée JA; Koten JW; Hennink WE; Den Otter W Int J Cancer; 2002 Mar; 98(1):134-40. PubMed ID: 11857397 [TBL] [Abstract][Full Text] [Related]
10. Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol. Azab AK; Kleinstern J; Doviner V; Orkin B; Srebnik M; Nissan A; Rubinstein A J Control Release; 2007 Nov; 123(2):116-22. PubMed ID: 17854940 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics. Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429 [TBL] [Abstract][Full Text] [Related]
12. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Cai S; Liu Y; Zheng Shu X; Prestwich GD Biomaterials; 2005 Oct; 26(30):6054-67. PubMed ID: 15958243 [TBL] [Abstract][Full Text] [Related]
14. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. Hahn SK; Oh EJ; Miyamoto H; Shimobouji T Int J Pharm; 2006 Sep; 322(1-2):44-51. PubMed ID: 16781096 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. II. Local interleukin 2 treatment of tumors of different immunogenic strength. Fiszer-Maliszewska L; Den Otter W; Madej JA; Mordarski M Arch Immunol Ther Exp (Warsz); 1998; 46(5):293-300. PubMed ID: 9832068 [TBL] [Abstract][Full Text] [Related]
16. Maintaining dimensions and mechanical properties of ionically crosslinked alginate hydrogel scaffolds in vitro. Kuo CK; Ma PX J Biomed Mater Res A; 2008 Mar; 84(4):899-907. PubMed ID: 17647237 [TBL] [Abstract][Full Text] [Related]
17. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. Konishi M; Tabata Y; Kariya M; Hosseinkhani H; Suzuki A; Fukuhara K; Mandai M; Takakura K; Fujii S J Control Release; 2005 Mar; 103(1):7-19. PubMed ID: 15710496 [TBL] [Abstract][Full Text] [Related]
18. Release of recombinant human interleukin-2 from dextran-based hydrogels. Cadée JA; de Groot CJ; Jiskoot W; den Otter W; Hennink WE J Control Release; 2002 Jan; 78(1-3):1-13. PubMed ID: 11772444 [TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449 [TBL] [Abstract][Full Text] [Related]
20. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor]. Dong LF; Mei HS; Song SX; Lu ZJ Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]